You can buy or sell MACK and other stocks, options, ETFs, and crypto commission-free!
Merrimack Pharmaceuticals, Inc. Common Stock, also called Merrimack Pharmaceuticals, is a clinical stage biopharmaceutical company, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Read More Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Yahoo FinanceMay 10
Merrimack Reports First Quarter 2019 Financial Results
CAMBRIDGE, Mass., May 10, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK), an oncology company focused on biomarker-defined cancers, today announced its first quarter 2019 financial results for the period ended March 31, 2019. "We continue to focus our efforts on completing the review of our strategic alternatives through which we are committed to optimizing value for our stockholders, including the preservation of potential contractual milestone payments Merrimack is eligible to receive," said...
-$0.78 per share